Glaukos to Release Third Quarter 2023 Financial Results after Market Close on November 1, 2023
11 Octubre 2023 - 6:00AM
Business Wire
Conference Call and Webcast Scheduled for 1:30
p.m. PT
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical
technology and pharmaceutical company focused on novel therapies
for the treatment of glaucoma, corneal disorders and retinal
diseases, plans to release third quarter 2023 financial results
after the market close on Wednesday, November 1, 2023. The
company’s management will discuss the results during a conference
call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on
November 1, 2023.
A link to the live webcast will be available on the company’s
website at http://investors.glaukos.com. To participate in the
conference call, please dial 888-210-2212 (U.S.) or 646-960-0390
(International) and enter Conference ID 7935742. A replay will be
archived on the company’s website following completion of the
call.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology
and pharmaceutical company focused on developing and
commercializing novel therapies for the treatment of glaucoma,
corneal disorders and retinal diseases. Glaukos first developed
Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the
traditional glaucoma treatment paradigm, launching its first MIGS
device commercially in 2012, and continues to develop a portfolio
of technologically distinct and leverageable platforms to support
ongoing pharmaceutical and medical device innovations. Products or
product candidates for each of these platforms are designed to
advance the standard of care through better treatment options
across the areas of glaucoma, corneal disorders and retinal
diseases.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231011795526/en/
Chris Lewis Vice President, Investor Relations and Corporate
Affairs (949) 481-0510 clewis@glaukos.com
Glaukos (NYSE:GKOS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Glaukos (NYSE:GKOS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024